1. Home
  2. CRESY vs NUVB Comparison

CRESY vs NUVB Comparison

Compare CRESY & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRESY
  • NUVB
  • Stock Information
  • Founded
  • CRESY 1936
  • NUVB 2018
  • Country
  • CRESY Argentina
  • NUVB United States
  • Employees
  • CRESY N/A
  • NUVB N/A
  • Industry
  • CRESY Real Estate
  • NUVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRESY Finance
  • NUVB Health Care
  • Exchange
  • CRESY Nasdaq
  • NUVB Nasdaq
  • Market Cap
  • CRESY 815.5M
  • NUVB 959.2M
  • IPO Year
  • CRESY 1997
  • NUVB N/A
  • Fundamental
  • Price
  • CRESY $12.09
  • NUVB $2.51
  • Analyst Decision
  • CRESY
  • NUVB Strong Buy
  • Analyst Count
  • CRESY 0
  • NUVB 6
  • Target Price
  • CRESY N/A
  • NUVB $7.00
  • AVG Volume (30 Days)
  • CRESY 235.0K
  • NUVB 3.0M
  • Earning Date
  • CRESY 02-07-2025
  • NUVB 02-27-2025
  • Dividend Yield
  • CRESY 8.21%
  • NUVB N/A
  • EPS Growth
  • CRESY N/A
  • NUVB N/A
  • EPS
  • CRESY N/A
  • NUVB N/A
  • Revenue
  • CRESY $751,941,316.00
  • NUVB $2,162,000.00
  • Revenue This Year
  • CRESY N/A
  • NUVB N/A
  • Revenue Next Year
  • CRESY N/A
  • NUVB $369.72
  • P/E Ratio
  • CRESY N/A
  • NUVB N/A
  • Revenue Growth
  • CRESY N/A
  • NUVB N/A
  • 52 Week Low
  • CRESY $6.56
  • NUVB $1.44
  • 52 Week High
  • CRESY $14.23
  • NUVB $4.16
  • Technical
  • Relative Strength Index (RSI)
  • CRESY 41.82
  • NUVB 42.25
  • Support Level
  • CRESY $12.64
  • NUVB $2.44
  • Resistance Level
  • CRESY $14.03
  • NUVB $2.77
  • Average True Range (ATR)
  • CRESY 0.74
  • NUVB 0.23
  • MACD
  • CRESY -0.16
  • NUVB -0.04
  • Stochastic Oscillator
  • CRESY 9.09
  • NUVB 6.40

About CRESY Cresud S.A.C.I.F. y A.

Cresud SACIF y A is engaged in agricultural business and urban properties and investment business. Under its agricultural business the company produces oilseed grains and cereals, sugar cane and meat. The Agricultural business of the company is further comprised of four reportable segments which are Agricultural production, Land transformation and Sales, Corporate and Other segments. The company participates in the real estate business in Argentina through its subsidiary IRSA. The real estate business is further comprised of five reportable segments, namely Shopping Malls, Offices, Sales and Developments, Hotels and others.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Share on Social Networks: